Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Allena Pharmaceuticals, Inc. ALNAQ OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Allena Pharmaceuticals, Inc. (ALNAQ) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $33M (loss), growing at -1.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $527,000 against $19M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 2.11 (strong liquidity). Debt-to-assets is 1.5%. Total assets: $35M.

Analyst outlook: 0 / 4 analysts rate ALNAQ as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

ALNAQ SharesGrow Score Overview

33/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALNAQ

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ALNAQ: +0%/yr revenue is, -1.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ALNAQ: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 2.11 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ALNAQ: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 4 analysts rate ALNAQ as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.0E-6-0.0185
Volume16.45K
Avg Volume (30D)24.85K
Market Cap$122.00
Beta (1Y)-14.54
Share Statistics
EPS (TTM)-1.03
Shares Outstanding$32.51M
IPO Date2017-11-02
Employees12
Financial Highlights & Ratios
EBITDA$-31.97M
Net Income$-33.36M
Operating Income$-32.34M
Total Cash$29.99M
Total Debt$527K
Net Debt$-29.46M
Total Assets$34.76M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusHold
Analysts Covering4
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD

Price Chart

Track all markets on TradingView
ALNAQ
Allena Pharmaceuticals, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology

People Also View

CMVLF
CMVLF
Cellectis S.A.
$3.08
-30.00%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 BITRF
BITRF
Biotron Limited
$0.03
+0.00%
 FWPAY
FWPAY
Forward Pharma A/S
$300.00
-25.09%
 CHNXF
CHNXF
ChitogenX Inc.
$0.01
+0.00%
 APTCF
APTCF
Advanced Proteome Therapeutics Corporation
$0.00
+0.00%
 MRZM
MRZM
Marizyme, Inc.
$0.00
+0.00%
 SCPS
SCPS
Scopus BioPharma Inc.
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message